SCIENCE

HAUS LABS BY LADY GAGA LAUNCHES IN EUROPE EXCLUSIVELY WITH SEPHORA, ACROSS 12 EU COUNTRIES

Retrieved on: 
Tuesday, March 26, 2024
Pigment, App, SKIN, PLUS, Beauty, Inflammation, Nikkie de Jager, DNA, CLEAN, Arnica, LIVE, SCIENCE, Skin, System, CMO, Sephora, Cosmetics

EL SEGUNDO, Calif., March 26, 2024 /PRNewswire/ -- HAUS LABS BY LADY GAGA, a science-driven, clean artistry brand propelled by HausTech Powered™ innovation, is expanding exclusively with Sephora across Europe - 12 new countries - following last year's successful UK launch. As of March 26, 2024, the brand will be in 15 countries around the world.

Key Points: 
  • The LIVE follows the success of the Sephora Europe App previews - where customers across 12 countries purchased HAUS LABS early, for an unprecedented four-day early access, online shopping experience.
  • Ben Jones, CEO of HAUS LABS BY LADY GAGA: "Europe is a critical milestone for HAUS LABS BY LADY GAGA.
  • Sylvie Moreau, President of Sephora Europe and the Middle East shared, "After the successful launch in Sephora UK, we are very excited to launch HAUS LABS BY LADY GAGA in our European market!
  • We are confident they will be thrilled to discover the creative and inspiring world of HAUS LABS BY LADY GAGA and thrilled to experience the brand's game-changing formulas."

HAUS LABS BY LADY GAGA LAUNCHES IN EUROPE EXCLUSIVELY WITH SEPHORA, ACROSS 12 EU COUNTRIES

Retrieved on: 
Tuesday, March 26, 2024
Pigment, App, SKIN, PLUS, Beauty, Inflammation, Nikkie de Jager, DNA, CLEAN, Arnica, LIVE, SCIENCE, Skin, System, CMO, Sephora, Cosmetics

EL SEGUNDO, Calif., March 26, 2024 /PRNewswire/ -- HAUS LABS BY LADY GAGA, a science-driven, clean artistry brand propelled by HausTech Powered™ innovation, is expanding exclusively with Sephora across Europe - 12 new countries - following last year's successful UK launch. As of March 26, 2024, the brand will be in 15 countries around the world.

Key Points: 
  • The LIVE follows the success of the Sephora Europe App previews - where customers across 12 countries purchased HAUS LABS early, for an unprecedented four-day early access, online shopping experience.
  • Ben Jones, CEO of HAUS LABS BY LADY GAGA: "Europe is a critical milestone for HAUS LABS BY LADY GAGA.
  • Sylvie Moreau, President of Sephora Europe and the Middle East shared, "After the successful launch in Sephora UK, we are very excited to launch HAUS LABS BY LADY GAGA in our European market!
  • We are confident they will be thrilled to discover the creative and inspiring world of HAUS LABS BY LADY GAGA and thrilled to experience the brand's game-changing formulas."

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024
Bias, Lung compliance, NON, SCIENCE, Tracheotomy, Acute myeloid leukemia, Mast cell activation syndrome, BTK, Alzheimer's disease, ANCOVA, Azacitidine, Missionary, B cell, Riluzole, CHMP, Guideline, NOD, Sickle cell disease, ALZ, Tablet, MECOM, AML, SCD, Biomarker, DSM-IV codes, Survival, Science, Prostate cancer, Oxygen, EMA, Docetaxel, Health Canada, ISM, FDA, Masitinib, Euronext, Cell, Chromosome abnormality, OS, UPDATE, Multiple sclerosis, COVID-19, Patient, Disease, Itch, RHU, CAFS, Failure, Depression, Pharmaceutical industry

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

PPG, PPG Foundation invested more than $17.5 million in communities worldwide in 2023

Retrieved on: 
Thursday, February 15, 2024
Technology, Retail, Consumer, Other Construction & Property, Home Goods, Other Education, Construction & Property, Other Philanthropy, Philanthropy, Education, Children, Fund Raising, Internet, Foundation, Engineering, Carnegie Science Center, Student, Multimedia, Investment, STEM, Exhibition, Volunteering, Life, Social responsibility, Mathematics, University, SCIENCE, School, Element, Organization, 500th, CREF, Science, Red, Workforce, AdoptAClassroom.org, Partnership, Tutoring

PPG (NYSE:PPG) and the PPG Foundation today announced that they invested more than $17.5 million worldwide in 2023, an increase of $1.3 million over 2022.

Key Points: 
  • PPG (NYSE:PPG) and the PPG Foundation today announced that they invested more than $17.5 million worldwide in 2023, an increase of $1.3 million over 2022.
  • View the full release here: https://www.businesswire.com/news/home/20240215307583/en/
    PPG and the PPG Foundation invested more than $17.5 million worldwide in 2023 to support over 450 community partners and programs that are focused on advancing education and delivering community sustainability while encouraging PPG employee volunteerism.
  • The PPG Foundation partnered with AdoptAClassroom.org to equip teachers and 10 schools in PPG communities with STEM education tools.
  • 60 COLORFUL COMMUNITIES® projects completed in 2023 in 16 countries:
    In 2023, PPG’s global Colorful Communities program reached its 500th project milestone .

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

TERA SCIENCE counts down its entry into the global environmental waste and new renewable energy market

Retrieved on: 
Friday, December 15, 2023
Ministry, SCIENCE, Social Problems, Research, Hydrogen, Technology transfer, CDS, Waste management, KRW, Atmosphere, R, TERA, Government, POSCO, Clothing, Fine chemical, Renewable energy, Environment

TERA SCIENCE will achieve waste management innovation with 5th generation CDS technology in South Korea's KRW 23.7 trillion market...

Key Points: 
  • TERA SCIENCE will achieve waste management innovation with 5th generation CDS technology in South Korea's KRW 23.7 trillion market...
  • CDS (Centrifugal Divided Space) technology is an innovative patented technology that dramatically combusts various wastes and converts them into energy.
  • TERA SCIENCE is expected to maximize corporate value by advancing into the waste treatment and new renewable energy fields using 6th generation CDS technology.
  • They say that TERA SCIENCE's waste-related renewable energy field should also be protected from technology transfer from Korea to overseas.

EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'

Retrieved on: 
Tuesday, October 17, 2023
Partnership, NUS, National university, Drug development, MDAX, Polaris Partners, SCIENCE, Duke–NUS Medical School, Therapy, RESEARCH, National University of Singapore, FOR, Agency for Science, Technology and Research, Patient, Bayer, EVO, Frankfurt Stock Exchange, Academic Partnerships, SE, Growth, Evotec, Public sector, Duke University, University, LEAPS, POLARIS, Drug discovery, ISIN, Agency, AND, Pharmaceutical industry, Research, Science

“65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.

Key Points: 
  • “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.
  • 65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore’s biotech ecosystem.
  • 65LAB selects promising academic projects and invests up to US$ 1.5 m in each project over the course of 18-24 months.
  • The Board provides oversight and governance to 65LAB’s strategy and operations and includes Dr Wen Qi Ho, Therapeutics Lead, ClavystBio, Dr Christina Isacson, Partner, Lightstone Ventures, Dr Pei Sze Ng, Director, Leaps by Bayer, and Dr Kim Png, Principal, Polaris Partners.

GUINNESS WORLD RECORDS 2024 Edition Released

Retrieved on: 
Thursday, September 14, 2023
Yoga, Hot, Young Achievers Award, Basketball, Male, Hair, BLUE, Human, Partnership, Tennis, Horns, Ninja, GUINNESS, GRACE, SCIENCE, Mammal, Clothing, Guinea, Record, The Care Bears Movie, Guinness, ARTS, Ship, GWR, Science, Guinness World Records, Athlete, Sasuke (TV series), Grace, Care Bears, Collection, Hula, Water, AMIR, Travel, Football, Rest, Book, Calf, Lake, Nightclub, Film industry, Entertainment, Jewellery, Rolling (metalworking), Amusement park, Video game, Jurassic Park

NEW YORK, Sept. 14, 2023 /PRNewswire/ -- GUINNESS WORLD RECORDS (GWR), the global authority on record-breaking achievements, announces that GUINNESS WORLD RECORDS™2024 (GWR2024) is available in stores and online today. The new edition includes 2,638 mind-blowing achievements from around the world.

Key Points: 
  • NEW YORK, Sept. 14, 2023 /PRNewswire/ -- GUINNESS WORLD RECORDS (GWR), the global authority on record-breaking achievements, announces that GUINNESS WORLD RECORDS™2024 (GWR2024) is available in stores and online today.
  • GUINNESS WORLD RECORDS 2024 is available for purchase in stores and online from Sept. 14, 2023.
  • Completing the illustrated Guinness World Records universe, the artwork takes the reader on a deep-sea odyssey to the bottom of the ocean.
  • GUINNESS WORLD RECORDS 2024 is available for purchase in stores and online from Sept. 14, 2023, with discounts widely available.

Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.

Retrieved on: 
Thursday, September 14, 2023
Research and development, Medical laboratory, Therapy, SCIENCE, Research fellow, Research, Biology, Pathology, Brown University, Internal medicine, Fibrosis, Alpert Medical School, Immunology, Pharmaceutical industry, Medicine, Ocean Biomedical, Malaria

Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next-generation biopharma company working to accelerate the development and commercialization of compelling new biopharma discoveries, will host a live Research & Development update with scientific co-founders, Dr. Jack A. Elias and Dr. Jonathan Kurtis today at 2:00 pm ET on their YouTube channel.

Key Points: 
  • The presentation will share information about two of Ocean Biomedical’s three current programs, Fibrosis and Malaria, discussing the original science underpinning Ocean’s efforts, the research progress to date, and the next steps envisioned.
  • Questions about Ocean’s Fibrosis or Malaria programs can be submitted in advance to [email protected] , or during the program using the chat function.
  • Dr. Jack A. Elias is a leader in pulmonary research and care.
  • Dr. Jonathan Kurtis is a global leader in malaria vaccine research, and his groundbreaking discoveries have been published in NATURE and SCIENCE.

British Skincare Brand ZELENS Hosts First Brand Ceremony in China, Setting the Standards in Skincare Excellence

Retrieved on: 
Thursday, September 7, 2023
Partnership, SO, Oxford, Marketing, SCIENCE, Biotechnology, Skin cancer, Research, Harvard University, Happiness, City, Growth, Skin, Pharmaceutical industry, Cosmetics

CHANGSHA, China, Sept. 7, 2023 /PRNewswire/ -- On September 7th, ZELENS, a pioneering British skincare brand renowned for its cutting-edge scientific approach, successfully held its first brand ceremony in China.

Key Points: 
  • CHANGSHA, China, Sept. 7, 2023 /PRNewswire/ -- On September 7th, ZELENS, a pioneering British skincare brand renowned for its cutting-edge scientific approach, successfully held its first brand ceremony in China.
  • The event also showcased ZELENS' comprehensive re-branding accomplishments from the previous three years, starting a new chapter for the brand.
  • The ZELENS brand ceremony not only celebrated its achievements but also solidified its partnership with S'Young International to bolster ZELENS' brand presence, product marketing and sales in the Chinese market.
  • The event reinforced ZELENS' dedication to providing scientifically advanced skincare solutions as it continues to revolutionize skincare solutions and elevate its global presence.